pp-202 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
Australia
GMP approvals
TGA
Comments
Indication: Myelofibrosis (MF) — in combination with ruxolitinib in JAK-inhibitor-naïve patients
Clinical stage: Phase 2 — ongoing (combination with ruxolitinib)
Modality: Small molecule (first-in-class SSAO/VAP-1 inhibitor)
Mechanism / Target: First-in-class inhibitor of SSAO (semicarbazide-sensitive amine oxidase) / VAP-1 (vascular adhesion protein-1); reduces inflammatory cell trafficking to the bone marrow, targeting marrow fibrosis and inflammation beyond JAK inhibition alone
Route / form: Oral
Differentiation: First-in-class SSAO/VAP-1 inhibitor with novel mechanism addressing bone marrow inflammatory trafficking; complementary to JAK inhibition (ruxolitinib); addresses residual disease activity not fully controlled by JAK inhibitors
Manufacturer #39339
Australia-based publicly listed clinical-stage drug-development company built on proprietary small-molecule enzyme chemistry. Rx oral and injectable pipeline targets blood cancers and conditions linked to inflammation and fibrosis. Advances candidates through early- and mid-stage clinical studies with regulatory engagement.
None